KraneShares Electric Vehicles and Future Mobility vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $27.56 (market cap $74.06M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 785.3× KraneShares Electric Vehicles and Future Mobility's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while KraneShares Electric Vehicles and Future Mobility pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 46 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| KARS | TAK | |
|---|---|---|
Market Cap | $74.06M | $58.16B |
Volume | 2,546 | 2,467,530 |
Sector | Sector/Thematic | Health |
52-Week High | $38.01 | $19.05 |
52-Week Low | $27.25 | $13.23 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | — | $86.04B |
Dividend Yield | — | 3.36% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →